false
0001091596
0001091596
2026-11-16
2026-11-16
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 16, 2026
Nuo Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
Delaware
|
000-28443
|
23-3011702
|
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
|
of incorporation)
|
File Number)
|
Identification No.)
|
8285 El Rio, Suite 190, Houston, Texas 77054
(Address of principal executive offices) (Zip Code)
(346) 396-4770
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
Securities registered pursuant to Section 12(b) of the Act: None
Indicate by check mark whether the Registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition
On November 16, 2026, Nuo Therapeutics, Inc. (“Nuo”) issued a press release announcing its financial results for the third quarter and first nine months of 2026. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference.
The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No.
|
Description
|
|
99
|
Press Release of Nuo Therapeutics, Inc. dated November 16, 2026
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Nuo Therapeutics, Inc.
|
|
| |
|
|
|
| |
|
|
|
| |
By:
|
/s/ David E. Jorden
|
|
| |
|
David E. Jorden
|
|
| |
|
Chief Executive and Chief Financial Officer
|
|
Date: November 17, 2026
Exhibit 99
|
|
8285 El Rio, Suite 190
Houston, TX 77054
Phone 833.298.6633
|
NUO THERAPEUTICS ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Final 2027 Medicare Reimbursement Rulings and Coverage Expansion to New Place of Service Reinforce Growth Outlook
Houston, TX – November 16, 2026 – Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the third quarter ended September 30, 2026 and provided an operational and business update.
Third Quarter and First Nine Months 2026 Financial Summary
| |
●
|
Total revenues of approximately $1.9 million and $4.9 million for the third quarter 2026 and first nine months of 2026, respectively, increased 80% and 123%, respectively, versus the comparable 2025 periods.
|
| |
●
|
Total product revenues in the third quarter increased 5% sequentially versus the second quarter 2026 with Aurix wound care revenues increasing approximately 17% sequentially which is the same average sequential growth rate over the past six quarters for Aurix wound care revenues.
|
| |
●
|
Third quarter net operating loss of approximately $374,000 improved by approximately $166,000 compared to third quarter 2025 while increasing approximately $208,000 sequentially versus the second quarter. The sequential increase primarily reflected higher stock-based compensation, credit loss provision expense, and more than $100,000 of elevated regulatory costs associated with component supply matters.
|
| |
●
|
Subsequent to quarter end, final funding of $325,000 was received under the loan agreement with total borrowings established at $2,000,000.
|
Operational and Business Update
| |
●
|
Received $250,000 reimbursement fee milestone pursuant to the 2025 distribution agreement with Smith+Nephew.
|
| |
●
|
Final Medicare OPPS (Outpatient Prospective Payment System) reimbursement ruling recently released for calendar 2027 with the per treatment G0465 national average reimbursement increasing to approximately $2,257 or 7% from 2026 with positive pricing actions for Aurix anticipated next year.
|
| |
●
|
Medicare’s PFS (Physician Fee Schedule) ruling established a G0465 national average reimbursement of approximately $1,020 in 2027 or a decrease of approximately 4%.
|
| |
●
|
Expansion of coverage and processing of G0465 claims for nursing home treatments (Medicare Place of Service 32) effective January 1, 2027 is expected to be positive for future growth.
|
“As many wound care market participants have commented, the broader wound care space remains unsettled resulting from the dramatic January change to reimbursement economics for skin substitutes/grafts which remained unchanged in the final 2027 rulings mentioned above,” commented David Jorden, Nuo’s Chief Executive and Financial Officer.
“We have also observed a shift of patients and wound care volumes back to hospital-based settings and enjoyed our highest quarter ever of Aurix revenues in the hospital setting,” continued Mr. Jorden. “Since this year’s first quarter, our HOPD Aurix sales as a percentage of total wound care sales has more than doubled. The economics in hospital settings are strong, and we will continue to pursue and emphasize growth opportunities in this segment. We remain confident that autologous PRP and Aurix in particular are well positioned for continued long term attractive growth.”
“As a business, we are prioritizing both reaching the revenue level required for operational breakeven and assessing opportunities to strengthen our capital structure to support Nuo’s next stage of growth. The funding of the secured notes under the loan agreement in several tranches this year was done with these priorities in mind,” concluded Mr. Jorden.
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Nuo’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo’s anticipated growth opportunities and market positioning, including in the hospital outpatient setting, expectations regarding Medicare reimbursement and coverage changes, including the expansion of coverage to nursing home treatments, and their impact on demand for and pricing of Aurix, anticipated pricing actions, movement toward breakeven operations, and Nuo's ability to strengthen its capital structure. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in Nuo’s public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.
Contact:
David Jorden
NUO THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
| |
|
September 30,
2026
|
|
|
December 31,
2025
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
|
|
|
Cash
|
|
$ |
80,941 |
|
|
$ |
548,946 |
|
|
Accounts receivable, net
|
|
|
1,410,322 |
|
|
|
561,667 |
|
|
Inventory, net
|
|
|
330,134 |
|
|
|
213,761 |
|
|
Prepaid expenses and other current assets
|
|
|
162,667 |
|
|
|
55,509 |
|
|
Total current assets
|
|
|
1,984,064 |
|
|
|
1,379,883 |
|
| |
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
704,903 |
|
|
|
366,315 |
|
|
Operating lease right of use assets
|
|
|
41,238 |
|
|
|
99,464 |
|
|
Total assets
|
|
$ |
2,730,205 |
|
|
$ |
1,845,662 |
|
| |
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' DEFICIT
|
|
|
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$ |
756,720 |
|
|
$ |
436,083 |
|
|
Accrued expenses
|
|
|
648,177 |
|
|
|
493,792 |
|
|
Deferred revenue
|
|
|
380,730 |
|
|
|
300,000 |
|
|
Current portion of notes payable
|
|
|
515,625 |
|
|
|
- |
|
|
Current portion of notes payable – related party
|
|
|
112,500 |
|
|
|
- |
|
|
Current portion of operating lease liabilities
|
|
|
40,756 |
|
|
|
76,410 |
|
|
Total current liabilities
|
|
|
2,454,508 |
|
|
|
1,306,285 |
|
| |
|
|
|
|
|
|
|
|
|
Deferred revenue – long term
|
|
|
951,826 |
|
|
|
975,000 |
|
|
Notes payable
|
|
|
961,875 |
|
|
|
300,000 |
|
|
Note payable – related party
|
|
|
210,500 |
|
|
|
200,000 |
|
|
Non-current portion of operating lease liabilities
|
|
|
- |
|
|
|
20,936 |
|
|
Total liabilities
|
|
|
4,578,709 |
|
|
|
2,802,221 |
|
| |
|
|
|
|
|
|
|
|
|
Stockholders' deficit
|
|
|
|
|
|
|
|
|
|
Common stock; $0.0001 par value, 100,000,000 shares authorized, 48,573,894 and 48,179,039 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
|
|
|
4,857 |
|
|
|
4,818 |
|
|
Additional paid-in capital
|
|
|
34,239,796 |
|
|
|
33,810,785 |
|
|
Accumulated deficit
|
|
|
(36,093,157 |
) |
|
|
(34,772,162 |
) |
|
Total stockholders' deficit
|
|
|
(1,848,504 |
) |
|
|
(956,559 |
) |
| |
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders' deficit
|
|
$ |
2,730,205 |
|
|
$ |
1,845,662 |
|
NUO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| |
|
Three Months
ended
September 30,
2026
|
|
|
Three Months
ended
September 30,
2025
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
Product sales
|
|
$ |
1,779,563 |
|
|
$ |
957,096 |
|
|
Distribution fee revenue
|
|
|
86,562 |
|
|
|
75,000 |
|
|
Total revenue
|
|
|
1,866,125 |
|
|
|
1,032,096 |
|
| |
|
|
|
|
|
|
|
|
|
Costs of sales
|
|
|
673,334 |
|
|
|
406,721 |
|
|
Gross profit
|
|
|
1,192,791 |
|
|
|
625,375 |
|
| |
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
1,567,223 |
|
|
|
1,165,517 |
|
|
Total operating expenses
|
|
|
1,567,223 |
|
|
|
1,165,517 |
|
| |
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(374,432 |
) |
|
|
(540,142 |
) |
| |
|
|
|
|
|
|
|
|
|
Other income (expense)
|
|
|
|
|
|
|
|
|
|
Interest income (expense), net
|
|
|
(51,099 |
) |
|
|
409 |
|
|
Other income
|
|
|
603 |
|
|
|
1,814 |
|
|
Total other income (expenses)
|
|
|
(50,496 |
) |
|
|
2,223 |
|
| |
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(424,928 |
) |
|
$ |
(537,919 |
) |
| |
|
|
|
|
|
|
|
|
|
Loss per common share
|
|
|
|
|
|
|
Basic and diluted
|
|
$ |
(0.01 |
) |
|
$ |
(0.01 |
) |
| |
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding
|
|
|
|
|
|
|
Basic and diluted
|
|
|
48,472,374 |
|
|
|
47,539,384 |
|
NUO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
| |
|
Nine Months
ended
September 30,
2026
|
|
|
Nine Months
ended
September 30,
2025
|
|
|
Revenue
|
|
|
|
|
|
|
|
|
|
Product sales
|
|
$ |
4,694,782 |
|
|
$ |
2,066,679 |
|
|
Distribution fee revenue
|
|
|
242,444 |
|
|
|
150,000 |
|
|
Total revenue
|
|
|
4,937,226 |
|
|
|
2,216,679 |
|
| |
|
|
|
|
|
|
|
|
|
Costs of sales
|
|
|
1,724,681 |
|
|
|
687,092 |
|
|
Gross profit
|
|
|
3,212,545 |
|
|
|
1,529,587 |
|
| |
|
|
|
|
|
|
|
|
|
Operating expenses
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative
|
|
|
4,199,995 |
|
|
|
3,466,898 |
|
|
Total operating expenses
|
|
|
4,199,995 |
|
|
|
3,466,898 |
|
| |
|
|
|
|
|
|
|
|
|
Loss from operations
|
|
|
(987,450 |
) |
|
|
(1,937,311 |
) |
| |
|
|
|
|
|
|
|
|
|
Other income (expense)
|
|
|
|
|
|
|
|
|
|
Interest income (expense), net
|
|
|
(340,447 |
) |
|
|
(33 |
) |
|
Other income
|
|
|
6,902 |
|
|
|
3,608 |
|
|
Total other income (expenses)
|
|
|
(333,545 |
) |
|
|
3,575 |
|
| |
|
|
|
|
|
|
|
|
|
Net loss
|
|
$ |
(1,320,995 |
) |
|
$ |
(1,933,736 |
) |
| |
|
|
|
|
|
|
|
|
|
Loss per common share
|
|
|
|
|
|
|
Basic and diluted
|
|
$ |
(0.03 |
) |
|
$ |
(0.04 |
) |
| |
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding
|
|
|
|
|
|
|
Basic and diluted
|
|
|
48,389,216 |
|
|
|
47,062,186 |
|